Business Description
PharmaCyte Biotech Inc
NAICS : 541714
SIC : 2836
ISIN : US71715X2036
Total Employee Number:
2Description
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.71 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -29.8 | |||||
3-Year EPS without NRI Growth Rate | -17.1 | |||||
3-Year FCF Growth Rate | -15.3 | |||||
3-Year Book Growth Rate | 20.7 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.08 | |||||
9-Day RSI | 28.16 | |||||
14-Day RSI | 32.73 | |||||
3-1 Month Momentum % | 6.65 | |||||
6-1 Month Momentum % | -5.98 | |||||
12-1 Month Momentum % | -24.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.33 | |||||
Quick Ratio | 12.33 | |||||
Cash Ratio | 12.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 31 | |||||
Shareholder Yield % | 2.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -7.75 | |||||
ROA % | -6.41 | |||||
ROIC % | -16.01 | |||||
3-Year ROIIC % | 0.04 | |||||
ROC (Joel Greenblatt) % | -1011.08 | |||||
ROCE % | -10.88 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.16 | |||||
Price-to-Tangible-Book | 0.17 | |||||
EV-to-EBIT | 2.5 | |||||
EV-to-EBITDA | 2.5 | |||||
EV-to-FCF | 2.81 | |||||
| Price-to-Net-Current-Asset-Value | 1.86 | |||||
| Price-to-Net-Cash | 1.52 | |||||
Earnings Yield (Greenblatt) % | 40 | |||||
FCF Yield % | -77.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PMCB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmaCyte Biotech Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.12 | ||
| Beta | 1.1357 | ||
| 3-Year Sharpe Ratio | -1.05 | ||
| 3-Year Sortino Ratio | -1.22 | ||
| Volatility % | 42.8 | ||
| 14-Day RSI | 32.73 | ||
| 14-Day ATR ($) | 0.048493 | ||
| 20-Day SMA ($) | 0.643975 | ||
| 12-1 Month Momentum % | -24.51 | ||
| 52-Week Range ($) | 0.55 - 1.51 | ||
| Shares Outstanding (Mil) | 10.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaCyte Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaCyte Biotech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-12-18 | In 139 days | ||
| First quarter earnings results for 2027 | 2026-09-15 | In 45 days | ||
| Annual report for 2026 | 2026-08-11 | In 10 days | ||
| General meeting for 2026 | 2026-03-30 11:00 | 0.71 (-13.55%) | ||
| Third quarter earnings results for 2026 | 2026-03-17 | 0.70 (+1.59%) | ||
| Second quarter earnings results for 2026 | 2025-12-18 | 0.82 (-14.06%) | ||
| First quarter earnings results for 2026 | 2025-09-15 | 1.04 (-0.95%) | ||
| Annual report for 2025 | 2025-08-11 | 0.83 (-2.35%) | ||
| General meeting for 2025 | 2025-04-24 11:00 | 1.19 (+3.48%) | ||
| Third quarter earnings results for 2025 | 2025-03-17 | 1.58 (-4.24%) |
Show
Entries
PharmaCyte Biotech Inc Frequently Asked Questions
What is PharmaCyte Biotech Inc(PMCB)'s stock price today?
The current price of PMCB is $0.58. The 52 week high of PMCB is $1.51 and 52 week low is $0.55.
When is next earnings date of PharmaCyte Biotech Inc(PMCB)?
The next earnings date of PharmaCyte Biotech Inc(PMCB) is 2026-09-15 Est..
Does PharmaCyte Biotech Inc(PMCB) pay dividends? If so, how much?
PharmaCyte Biotech Inc(PMCB) does not pay dividend.
Guru Commentaries on NAS:PMCB
No articles.
Press Release
Articles on PharmaCyte Biotech Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers